Emergence and Genomic Characterization of a spa Type t4407 ST6-SCCmec Type IVa Methicillin-Resistant Staphylococcus aureus Strain Isolated from Al-Karak Hospital, Jordan.

Background and Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a major concern in Jordanian hospitals in terms of infection control. The purpose of this study was to identify the resistance patterns of Staphylococcus aureus strains isolated from surfaces of critical locations within the Al-Karak Governmental Hospital in 2019. Additionally, the study aimed to conduct whole-genome sequencing on the isolates. Materials and Methods: In February 2019, fourteen S. aureus strains were isolated from surfaces in critical sites in the Al-Karak Governmental Hospital. These isolates underwent antibiogram testing to determine their resistance profile. Genome sequencing using the Illumina MiSeq platform was applied to the extracted DNA from these isolates. The genomic data, including coding sequences, were analyzed to identify lineage, resistance genes, and plasmids. Results: The antibiogram results revealed that 11 of the 14 isolates were resistant to oxacillin, 6 to linezolid, and 1 to rifampicin, while none showed resistance to chloramphenicol. Eleven isolates were identified as MRSA, with a novel spa type (t4407) not previously reported in Jordan. High-quality sequencing data were obtained for only one isolate, i.e., A29, the genome showed 2,789,641 bp with a 32.7% GC content and contained 2650 coding sequences. Genomic analysis indicated the ST6 lineage, mecA gene (SCCmec type IVa(2B)), and a hybrid plasmid (pJOR_blaZ) carrying the blaZ gene for ß-lactam resistance. Genomic data were deposited in NCBI (CP104989). The A29 genome closely resembled an MRSA genome isolated from a Danish hospital in 2011. The SNP analysis revealed identical antimicrobial resistance genes in these two genomes. Conclusions: This study unveils the first genomic sequence of an MRSA isolate from Jordan, marked by distinctive genotypic traits. The findings enhance our understanding of the MRSA types circulating in Jordan and the region and substantiate the phenomenon of intercontinental MRSA transmission.

Antibacterial, antioxidant, and cytotoxic activities of Syzygium aromaticum (L.) Merr. & Perry essential oil with identification of its chemical constituents.

Aromatic plants embrace volatile compounds with efficiency in treating different diseases. In Jordan, Syzygium aromaticum flower buds (clove) are extensively used as folk medicine without awareness of its bio-safe dosage. Herein, clove buds were hydrodistilled using the Clevenger apparatus, and the resulting essential oil (CEO) was analyzed using Gas Chromatography-Mass Spectrometry (GC-MS). The antibacterial activity was evaluated against tested bacterial strains by agar diffusion test and micro-broth dilution assay. The antioxidant capacity was assessed using DPPH radical scavenging assay, while the cytotoxic potency was unraveled by determination of its anti-proliferative activity against MDA-MB-231 breast adenocarcinoma and normal Vero cell lines. CEO yield was 5.7 ± 1.3% (w/w); encompassed 24 volatile ingredients with eugenol as the principal compound (73.41%). The CEO inhibited the growth of both Gram-positive and Gram-negative bacterial test strains, causing the formation of 13.7 ± 1.5-17.3 ± 0.6 mm and 11.7 ± 1.5-20.7 ± 1.2 mm inhibition zones, respectively with MIC 1.25-5 µL/mL. Moreover, it showed antioxidant activity with IC50 0.0016 ± 0.0001 µL/mL (1.6 ± 0.1 µg/mL, 2.98 ± 0.4 µg Trolox®/µg CEO). Intriguingly, the CEO was cytotoxic against both cancerous and noncancerous cell lines at IC50 of 0.25 ± 0.02 µL/mL and 0.18 ± 0.01 µL/mL, respectively. Herein results unveil the potential application of CEO as a pharmaceutical remedy with considering its bio-safe dosage.